Frankie Powell, MD
Hematology & Oncology · Newport News, VANPI 1780175554
Payments from drug & device makers
Across 198 payments — averaging $25.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$590
- AstraZeneca$453
- Novartis$400
- AbbVie$314
- Genentech USA, Inc.$273
- Incyte Corporation$242
- plus $3K from 36 others
What the payments were for
- Food & beverage$4,78194%
- Education$3046%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 25 | $590 |
| AstraZeneca(2 entities) | 14 | $453 |
| Novartis | 22 | $400 |
| AbbVie | 12 | $314 |
| Genentech USA, Inc. | 9 | $273 |
| Incyte Corporation | 4 | $242 |
| Merck | 12 | $225 |
| Seagen Inc. | 6 | $211 |
| Genmab U.S., Inc. | 4 | $175 |
| GSK | 9 | $171 |
| Pfizer | 8 | $156 |
| Eisai Inc. | 8 | $143 |
| E.r. Squibb & Sons, L.L.C. | 7 | $143 |
| Johnson & Johnson | 9 | $135 |
| Gilead | 1 | $117 |
| Janssen Scientific Affairs, LLC | 1 | $113 |
| Amgen | 1 | $100 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $98 |
| Lilly USA, LLC | 1 | $95 |
| Astellas Pharma US Inc | 4 | $73 |
| Bristol Myers Squibb | 5 | $73 |
| Karyopharm Therapeutics Inc. | 3 | $72 |
| Bayer | 4 | $71 |
| Genentech, Inc. | 1 | $69 |
| Jazz Pharmaceuticals Inc. | 2 | $66 |
| Puma Biotechnology, Inc. | 3 | $59 |
| Beigene USA, Inc. | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Sobi, Inc | 2 | $47 |
| Sanofi | 2 | $46 |
| Mirati Therapeutics, Inc. | 2 | $30 |
| Array Biopharma Inc | 1 | $26 |
| Syndax Pharmaceuticals, Inc. | 1 | $24 |
| Dova Pharmaceuticals | 1 | $23 |
| Caris MPI, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| ADC Therapeutics America, Inc. | 1 | $20 |
| BTG International Inc. | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Taiho Oncology, Inc. | 1 | $15 |
| Rigel Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,085 in reported general payments places this provider in the 55th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| InqoviDecitabine/Cedazuridine | 16 | $131,525 |
| EliquisApixaban | 40 | $30,868 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 47 | $1,046 |
| Oxycodone Hcl | 45 | $926 |
| Morphine Sulfate ErMorphine Sulfate | 27 | $828 |
| Prochlorperazine Maleate | 26 | $719 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $608 |
| Ondansetron Hcl | 33 | $537 |
| Dexamethasone | 27 | $495 |
| Gabapentin | 20 | $279 |
| Pantoprazole Sodium | 26 | $277 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $274 |
| Acyclovir | 14 | $177 |
| Potassium Chloride | 15 | $126 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Taiho Oncology, Inc.Inqovi | $15 | $131,52516 claims |
| PfizerEliquis | $156 | $30,86840 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Newport News
- David ChangNewport News$1.2M
- Graham WatsonNewport News$779K
- Craig PortellCharlottesville$12.9M
- Amanda Gillespie-TwardyRoanoke$12.2M
- Sekwon JangFairfax$11.8M
- Mark FlemingHampton$10M
- Mark KochenderferRoanoke$8.6M
- Mitul GandhiManassas$6.9M
- Michael DansoNorfolk$6.9M
- Jerome GoldschmidtChristiansburg$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.